You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Etanercept (Enbrel®) alternative storage at ambient temperature
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, July 2017
|
| DOI | 10.2147/cpaa.s131832 |
| Pubmed ID | |
| Authors |
Edel Shannon, Joanne Daffy, Heather Jones, Andrea Paulson, Steven M Vicik |
| Abstract |
Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors such as etanercept (Enbrel(®)), have improved outcomes for patients with rheumatic and other inflammatory diseases, with sustained remission being the optimal goal for patients with rheumatoid arthritis. Flexible and convenient treatment options, compatible with modern lifestyle, are important in helping patients maintain treatment and manage their disease. Etanercept drug product (DP) is available in lyophilized powder (Lyo) for solution injection, prefilled syringe, and prefilled pen presentations and is typically stored under refrigerated conditions. We aimed to generate a comprehensive analytical data package from stability testing of key quality attributes, consistent with regulatory requirements, to determine whether the product profile of etanercept is maintained at ambient temperature. Test methods assessing key attributes of purity, quality, potency, and safety were performed over time, following storage of etanercept DP presentations under a range of conditions. Results and statistical analysis from stability testing (based on size exclusion high-performance liquid chromatography, hydrophobic interaction chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis Coomassie) across all etanercept presentations (10 and 25 mg/vial Lyo DP; 25 and 50 mg prefilled syringe DP; 50 mg prefilled pen DP) showed key stability-indicating parameters were within acceptable limits through the alternative storage condition of 25°C±2°C for 1 month. Stability testing performed in line with regulatory requirements supports a single period of storage for etanercept DP at an alternative storage condition of 25°C±2°C for up to 1 month within the approved expiry of the product. This alternative storage condition represents further innovation in the etanercept product lifecycle, providing greater flexibility and enhanced overall convenience for patients. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 38% |
| United States | 4 | 31% |
| Saudi Arabia | 1 | 8% |
| India | 1 | 8% |
| Unknown | 2 | 15% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 69% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
| Scientists | 1 | 8% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 21% |
| Other | 2 | 11% |
| Student > Doctoral Student | 2 | 11% |
| Researcher | 2 | 11% |
| Student > Master | 2 | 11% |
| Other | 1 | 5% |
| Unknown | 6 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Chemical Engineering | 1 | 5% |
| Other | 4 | 21% |
| Unknown | 6 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2018.
All research outputs
#2,048,912
of 25,608,265 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#14
of 179 outputs
Outputs of similar age
#38,262
of 327,410 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#1
of 4 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,410 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them